EMD

5.66%

5.0¢

EMYRIA LIMITED

Market Cap $20.44M Add to my watchlist

Healthcare

Emyria Limited is an Australia-based clinical services and drug development company. The... Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Latest Threads

Tag

Subject

EMD Medicine

ASX Video: Emyria (ASX:EMD) to scale-up MDMA-assisted therapy

10/05/24

752

10/05/24

Last post FiSaver

752

EMD

Ann: Change in substantial holding

10/05/24

1.2K

10/05/24

Last post subi1

1.2K

EMD

Ann: Section 708A(5)(e) Notice

07/05/24

179

07/05/24

Last post

ASX News

179

EMD

Ann: Notification regarding unquoted securities - EMD

07/05/24

156

07/05/24

Last post

ASX News

156

EMD

Ann: Application for quotation of securities - EMD

07/05/24

159

07/05/24

Last post

ASX News

159

EMD

Ann: March 2024 Quarterly Activities Report and Appendix 4C

03/05/24

5.2K

03/05/24

Last post rasberry

5.2K

EMD

CEO Podcast

23/04/24

498

23/04/24

Last post gavint66

498

EMD

News: EMD Emyria Receives Bids Of A$2.3M To Expand Clinical Services

23/04/24

157

23/04/24

Last post

Hot News

157

See All Discussions

Timeline

Change in substantial holding
10 May 08:17	Share

Section 708A(5)(e) Notice
07 May 18:42	Share

Notification regarding unquoted securities - EMD
07 May 18:39	Share

Application for quotation of securities - EMD
07 May 18:37	Share

March 2024 Quarterly Activities Report and Appendix 4C
26 Apr 08:40	Share

Proposed issue of securities - EMD
23 Apr 09:54	Share

Emyria Receives Bids of $2.3M to Expand Clinical Services
23 Apr 09:53	Share

Trading Halt
19 Apr 09:14	Share

Emyria Opens Empax Centre to Advance Mental Health Care
10 Apr 08:23	Share

Emyria Expands Specialist AP Team - First Female for MDMA-AT
05 Apr 08:25	Share

Emyria, Reach Wellness Enter MDMA-AT Research Agreement
03 Apr 08:25	Share

Notification of cessation of securities - EMD
19 Mar 18:19	Share

Response to ASX Aware Query
12 Mar 17:58	Share

Response to ASX Price Query
08 Mar 09:56	Share

Emyria Half Year Results FY2024
29 Feb 09:25	Share

Appendix 4D and Half Year End Financial Report
28 Feb 17:28	Share

Notification of cessation of securities - EMD
23 Feb 19:47	Share

Webinar Presentation
02 Feb 08:23	Share

December 2023 Quarterly Activities Report and Appendix 4C
31 Jan 09:32	Share

Notification of cessation of securities - EMD
30 Jan 11:11	Share

Emyria Receives $2.5M R&D Tax Incentive Refund
15 Jan 09:29	Share

Company Overview and Strategic Update
10 Jan 09:31	Share

Emyria Specialist Granted Authorised Prescriber Status
10 Jan 09:28	Share

Change of Director's Interest Notice - M. Winlo
02 Jan 19:43	Share

Change in Substantial Holding
27 Nov 08:21	Share

Notification of cessation of securities - EMD
27 Nov 08:19	Share

Initial Director's Interest Notice - G. Hutchinson
22 Nov 08:59	Share

Final Director's Interest Notice - S. Washer
22 Nov 08:58	Share

Eminent Healthcare Leader New Independent Non-Exec Chair
21 Nov 09:45	Share

Application for quotation of securities - EMD
21 Nov 09:42	Share

View More

(20min delay)
Last 5.0¢		Change -0.003(5.66%)		Mkt cap ! $20.44M

Open	High	Low	Value	Volume
5.1¢	5.2¢	5.0¢	$17.13K	342.3K

Buyers (Bids)

No.	Vol.	Price($)
1	755	5.0¢

Sellers (Offers)

Price($)	Vol.	No.
5.2¢	99440	1

View Market Depth

No.	Vol.	Price($)
1	755	0.050
2	29000	0.049
1	23261	0.048
3	59579	0.047
6	276059	0.046

Price($)	Vol.	No.
0.052	99440	1
0.053	19534	1
0.054	10170	1
0.055	100000	2
0.059	80000	1

Last trade - 14.52pm 14/05/2024 (20 minute delay)


Last 5.2¢		Change -0.003 ( 1.96 %)
Open	High	Low	Volume
5.0¢	5.2¢	5.0¢	28200
Last updated 15.58pm 14/05/2024 ?

EMD (ASX) Chart

EMYRIA LIMITED

Latest Threads

Meet Sun Silver (ASX:SS1) - ASX's newest silver player based in Nevada, USA. With a 292,000,000 Oz silver equivalent resource, trading commences 15th May 2024, 11am AEST

Timeline

Featured News

Latest Videos

Emyria (ASX:EMD) recruits first patient in MDMA-assisted therapy trial for PTSD

10 Jul 2023 12:47 (AEST)

Emyria (ASX:EMD) pockets more than $2m R&D tax refund

12 Jan 2023 10:34 (AEDT)

Latest Articles

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair has funded the company $0.3M on Tuesday.

Emyria launches Empax Centre - pioneering innovation in mental health treatment

Emyria Limited has opened the Empax Centre, a cutting-edge facility designed to advance innovative mental health treatments, including psychedelic-assisted therapies.

Emyria hits milestone in PTSD treatment with first female specialist for MDMA therapy

Emyria has nominated its first female psychiatrist to treat post-traumatic stress disorder using the drug ecstasy.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News